Emicizumab Injection
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hemophilia A, Acquired
Conditions
Hemophilia A, Acquired
Trial Timeline
Mar 23, 2021 → Jan 4, 2023
NCT ID
NCT04188639About Emicizumab Injection
Emicizumab Injection is a phase 2 stage product being developed by Roche for Hemophilia A, Acquired. The current trial status is completed. This product is registered under clinical trial identifier NCT04188639. Target conditions include Hemophilia A, Acquired.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04188639 | Phase 2 | Completed |
Competing Products
20 competing products in Hemophilia A, Acquired
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + rFVIIa + aPCC | Chugai Pharmaceutical | Phase 3 | 77 |
| Human Coagulation Factor VIII | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + Factor VIII (FVIII) | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Roche | Phase 3 | 77 |
| HEMLIBRA | Johnson & Johnson | Pre-clinical | 23 |
| Emicizumab | Roche | Phase 3 | 77 |
| Emicizumab | Roche | Approved | 85 |
| Emicizumab | Roche | Phase 3 | 77 |
| SPK-8011QQ | Roche | Phase 1/2 | 41 |
| NXT007 | Roche | Phase 1/2 | 41 |
| Bypassing Agents + FVIII Replacement | Roche | Pre-clinical | 23 |
| PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086 | Pfizer | Phase 2 | 51 |
| Nonacog Alfa (Genetical Recombination) | Pfizer | Pre-clinical | 22 |
| Refacto AF | Pfizer | Pre-clinical | 22 |
| PF-06838435/ fidanacogene elaparvovec | Pfizer | Phase 3 | 76 |
| ReFacto AF | Pfizer | Phase 3 | 76 |
| Nonacog alfa + Nonacog alfa | Pfizer | Phase 3 | 76 |